JSSH
ALNY icon

J. Safra Sarasin Holding’s Alnylam Pharmaceuticals ALNY Stock Holding History

J. Safra Sarasin Holding’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.38M Buy
7,921
+4,691
+145% +$1.41M 0.03% 234
2026
Q1 		$1.07M Sell
3,230
-5,908
-65% -$2.01M 0.02% 279
2025
Q4 		$3.63M Sell
9,138
-384
-4% -$170K 0.06% 149
2025
Q3 		$4.34M Sell
9,522
-5,474
-37% -$2.23M 0.07% 143
2025
Q2 		$4.89M Sell
14,996
-1,439
-9% -$398K 0.08% 135
2025
Q1 		$4.44M Sell
16,435
-2,707
-14% -$696K 0.08% 140
2024
Q4 		$4.5M Buy
19,142
+7,868
+70% +$2.07M 0.08% 144
2024
Q3 		$3.1M Buy
11,274
+4,403
+64% +$1.15M 0.05% 171
2024
Q2 		$1.67M Buy
+6,871
New +$1.08M 0.03% 243

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Safra Sarasin Holding's ALNY Position: Q2 2026 in Review

J. Safra Sarasin Holding increased its Alnylam Pharmaceuticals (ALNY) stake by 145% in Q2 2026, buying an estimated $1.41M and bringing the position to 7,921 shares worth $2.38M. The position accounts for 0.03% of the portfolio, ranked #234.

J. Safra Sarasin Holding first reported a position in ALNY in Q2 2024 and has held it in 9 quarters since. The position peaked at $4.89M in Q2 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • J. Safra Sarasin Holding held 7,921 shares of Alnylam Pharmaceuticals worth $2.38M as of Q2 2026.
  • J. Safra Sarasin Holding bought 4,691 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.41M.
  • Alnylam Pharmaceuticals made up 0.03% of J. Safra Sarasin Holding's portfolio in Q2 2026, its #234 holding.
  • J. Safra Sarasin Holding first reported a position in Alnylam Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • J. Safra Sarasin Holding's Alnylam Pharmaceuticals position peaked at $4.89M in Q2 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on J. Safra Sarasin Holding's 13F filing for Q2 2026, filed 31 Jul 2026.